On Jan 5, 2019 Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded By Guggenheim From “Neutral”.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Corporate Logo

During Q3 2018 the big money sentiment decreased to 1.14. That’s change of 0.05, from 2018Q2’s 1.19. 39 investors sold all, 173 reduced holdings as Regeneron Pharmaceuticals, Inc. ratio fall. 153 grew holdings while 89 funds acquired holdings. Funds hold 70.41 million shares thus 0.23% more from 2018Q2’s 70.25 million shares.

Great West Life Assurance Can reported 0.05% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Putnam Invs Ltd Co invested in 0% or 1,019 shs. Huntington Comml Bank accumulated 4,927 shs. Citadel owns 43,033 shs. Johnson Grp owns 50 shs for 0% of their capital. Nelson Van Denburg Campbell Wealth Mngmt Limited Co invested in 0.17% or 1,916 shs. First Personal Fincl Svcs reported 63 shs stake. Moreover, Texas Permanent School Fund has 0.1% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). 38 were accumulated by Hilton Cap Mgmt Lc. Mcdaniel Terry And has invested 0.07% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Merian Glob (Uk) Ltd holds 0.11% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) or 39,421 shs. Lazard Asset Llc stated it has 6 shs. Bradley Foster Sargent Inc Ct reported 904 shs stake. Endurance Wealth Mngmt Incorporated invested in 0% or 30 shs. 1832 Asset Ltd Partnership reported 0% stake.

Regeneron Pharmaceuticals, Inc. registered $46.41 million net activity with 0 insider purchases and 7 selling transactions since July 9, 2018. Another trade for 104,552 shs valued at $42.52 million was sold by Sanofi. VAGELOS P ROY sold $27.42M worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) or 74,670 shs on Monday, July 9. Shares for $663,381 were sold by Fenimore Christopher R. on Wednesday, December 19. The insider GOLDSTEIN JOSEPH L sold 2,709 shs worth $1.09M.

Guggenheim Upgraded Regeneron Pharmaceuticals (NASDAQ:REGN)’s Rating to “Buy”.

It was announced on 4 January that Guggenheim upped Regeneron Pharmaceuticals (NASDAQ:REGN)‘s rating to “Buy”. REGN’s old rating was “Neutral”.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Ratings Coverage

A total of 8 analysts rate Regeneron Pharmaceuticals (NASDAQ:REGN) as follows: 3 “Buy”, 4 “Hold” and 1 “Sell”. Š¢herefore 38% are bullish. (NASDAQ:REGN) has 11 ratings reports on Jan 5, 2019 according to StockzIntelligence. On Thursday, October 11 the firm has “Hold” rating given by Canaccord Genuity. On Friday, December 14 the rating was upgraded by Goldman Sachs to “Buy”. The company rating was upgraded by Guggenheim on Friday, January 4. On Thursday, October 11 the firm earned “Equal-Weight” rating by Morgan Stanley. On Friday, August 3 the firm has “Equal-Weight” rating by Morgan Stanley given. On Friday, July 13 the rating was maintained by Morgan Stanley with “Equal-Weight”. On Monday, July 16 Argus Research maintained Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) with “Buy” rating. On Friday, August 3 Canaccord Genuity maintained Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) rating. Canaccord Genuity has “Hold” rating and $390 target. On Friday, August 3 the stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) earned “Neutral” rating by Robert W. Baird. On Monday, August 6 the stock has “Underweight” rating by Barclays Capital.

REGN touched $397.55 during the last trading session after $25.47 change.Regeneron Pharmaceuticals, Inc. is uptrending after having risen 1.07% since January 5, 2018. REGN has 1.21 million volume or 59.18% up from normal. The stock outperformed the S&P500 by 1.07%.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is anticipated to report earnings on February, 14., Faxor reports. Analysts predict $5.10 EPS, which is $0.64 up or 14.35 % from 2018’s $4.46 EPS. In case of $5.10 EPS REGN’s profit could reach $551.44 million. Analysts at Wall Street see Regeneron Pharmaceuticals, Inc.’s 0.00 % EPS growth compared to $5.10 EPS for last quarter.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, makes, and commercializes medicines for the treatment of serious medical conditions worldwide.The company has $42.99 billion market cap. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema ; myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.25.45 is the P/E ratio. It also provides Dupixent injection to treat adult patients with moderate-to-severe atopic dermatitis; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and Kevzara solution for subcutaneous injection to treat rheumatoid arthritis in adults.

For more Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) news published briefly go to: Seekingalpha.com, 247Wallst.com, Seekingalpha.com, Nasdaq.com or Seekingalpha.com. The titles are as follows: “Goldman bearish on Walgreens Boots Alliance in premarket analyst action; shares down 4% premarket – Seeking Alpha” published on December 14, 2018, “Top Analyst Upgrades and Downgrades: Bed Bath & Beyond, CBOE, eBay, Etsy, Intel, Netflix, Nokia, Snap, UTC, Vonage and More – 24/7 Wall St.” on January 04, 2019, “Regeneron Q3 top line up 11%; earnings up 53% – Seeking Alpha” with a publish date: November 06, 2018, “Time to Focus on Regeneron Pharmaceuticals (REGN) for Strong Earnings Growth Potential – Nasdaq” and the last “Will Regeneron Close At $400? – Seeking Alpha” with publication date: August 22, 2018.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.